ASH Dec 12, 2022 ASH Data Suggests CAR T is Best Option for Lymphoma Patients Expressing Both MYC, BCL-2 Premium Dec 11, 2022 Polygenic Risk Score Shows Potential in Personalizing Chemotherapy for Pediatric AML Patients Premium Dec 11, 2022 Bristol Myers Squibb, 2seventybio's Abecma Shows Benefit in High-Risk Multiple Myeloma Patients Premium Dec 11, 2022 Menin Inhibitors Show Activity in AML With NPM1, KMT2A Alterations Premium Dec 15, 2021 Researchers Report on Novel Pediatric AML Subtype Associated With Poor Outcomes at ASH Meeting Dec 14, 2021 Novartis' Kymriah Flops in Second-Line LBCL, Puzzling Oncologists After Yescarta, Breyanzi Successes Dec 14, 2021 Tibsovo, Azacitidine Combo Shows Improved Survival, Response in Newly Diagnosed IDH1-Mutant AML Dec 14, 2021 Researchers Showcase Potential of ctDNA Testing to Diagnose, Assess Prognosis in CNS Lymphoma Patients Premium Dec 13, 2021 Whole-Genome Sequencing Elucidates Lymphoma Patients' Response to CD19 CAR T-Cell Therapy Premium Dec 12, 2021 Gene Expression Signature IDs Multiple Myeloma Best Responders to Karyopharm's Xpovio in ASH Study Dec 12, 2021 CAR T-Cell Therapies Continue March Toward Earlier Lymphoma Treatment Lines, New ASH Data Show Premium Dec 8, 2020 NGS Bests Flow Cytometry for MRD-Based Prediction of ALL Relapse, Survival, ASH Study Suggests Premium Dec 8, 2020 Viracta to Launch Global Registration Trial for Nanatinostat, Valganciclovir in EBV-Positive Lymphoma Dec 8, 2020 ASH Studies Show Predictive Power of Undetectable MRD in Fixed-Duration CLL Regimens Premium Dec 6, 2020 ASH Studies Suggest CD19 CAR T-Cell Efficacy in New Patient Populations, Earlier Treatment Settings Premium Dec 6, 2020 Pfizer Reports Positive Phase II Trial of BRAF, MEK Inhibitor Combo in Multiple Myeloma Premium Dec 6, 2020 Lymphoma Patients With Aberrant CD58 Don't Derive Durable CAR T-cell Benefit, Study Shows Premium Dec 6, 2020 ASH Study Highlights Race-Based Survival Disparities, Distinct Molecular Features in AML Patients Premium Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
